Dr Bal Hari Poudel is Research Associate at the CMMIT, Murdoch University. He completed his PhD studies in molecular medicine at the Murdoch University. His experience extends to the realm of antisense-based technology, where he has applied it to address rare diseases such as dysferlinopathies and receptor modification for SARS-CoV-2. Presently, his research centers on osteosarcoma, where Dr. Poudel is actively engaged in testing oligonucleotides designed to downregulate specific high-priority targets identified through whole transcriptome analysis.
